CompletedPhase 2NCT02281760

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Studying Erdheim-Chester disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Human Genome Research Institute (NHGRI)
Principal Investigator
William A Gahl, M.D.
National Human Genome Research Institute (NHGRI)
Intervention
Dabrafenib Mesylate(drug)
Enrollment
9 enrolled
Eligibility
18-80 years · All sexes
Timeline
20142018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02281760 on ClinicalTrials.gov

Other trials for Erdheim-Chester disease

Additional recruiting or active studies for the same condition.

See all trials for Erdheim-Chester disease

← Back to all trials